[go: up one dir, main page]

PE20151601A1 - Compuestos novedosos de pirimidina y piridina y su uso - Google Patents

Compuestos novedosos de pirimidina y piridina y su uso

Info

Publication number
PE20151601A1
PE20151601A1 PE2015001855A PE2015001855A PE20151601A1 PE 20151601 A1 PE20151601 A1 PE 20151601A1 PE 2015001855 A PE2015001855 A PE 2015001855A PE 2015001855 A PE2015001855 A PE 2015001855A PE 20151601 A1 PE20151601 A1 PE 20151601A1
Authority
PE
Peru
Prior art keywords
pyridine compounds
novel pyrimidine
ethylpiperazin
methylbenzamide
pyrimidin
Prior art date
Application number
PE2015001855A
Other languages
English (en)
Inventor
Wei-Guo Su
Weihan Zhang
Jinshui Li
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of PE20151601A1 publication Critical patent/PE20151601A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a compuestos de pirimidina y piridina de la formula (I) o una sal farmaceuticamente aceptable del mismo. Donde X es CH2; Y es CH2, entre otros; G es N o CH; R1 es arilo, entre otros.; R2 es alquilo C1-C6, entre otros; R3 y R4 son hidrogeno, halogeno, etc.; R5 es alquilo C1-C6, entre otros. Son compuestos preferidos : [3-(2-(2-((4-(4-etilpiperazin-1-il)fenil)amino)pirimidin-5-il)etil)-5-metoxi-N-metilbenzamida]; [3-(2-(2-((3-(4-etilpiperazin-1-il)fenil)amino)pirimidin-5-il)etil)-5-metoxi-N-metilbenzamida]. Se refiere tambien a una composicion farmaceutica y a un proceso para la preparacion de los mismos, y su uso en la terapia de una enfermedad sensible a la inhibicion de FGFR, por ejemplo, cancer. .
PE2015001855A 2013-03-15 2014-03-14 Compuestos novedosos de pirimidina y piridina y su uso PE20151601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/072690 WO2014139145A1 (en) 2013-03-15 2013-03-15 Novel pyrimidine and pyridine compounds and usage thereof

Publications (1)

Publication Number Publication Date
PE20151601A1 true PE20151601A1 (es) 2015-11-02

Family

ID=51535826

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001855A PE20151601A1 (es) 2013-03-15 2014-03-14 Compuestos novedosos de pirimidina y piridina y su uso

Country Status (32)

Country Link
US (2) US20160052926A1 (es)
EP (1) EP2970120B1 (es)
JP (1) JP6109969B2 (es)
KR (1) KR101697982B1 (es)
CN (1) CN105143185B (es)
AR (1) AR095430A1 (es)
AU (1) AU2014231437B2 (es)
BR (1) BR112015020772B1 (es)
CA (1) CA2900748C (es)
CL (1) CL2015002520A1 (es)
CY (1) CY1121804T1 (es)
DK (1) DK2970120T3 (es)
EA (1) EA028654B1 (es)
ES (1) ES2697697T3 (es)
HR (1) HRP20181906T1 (es)
IL (1) IL240790B (es)
LT (1) LT2970120T (es)
MX (1) MX363397B (es)
MY (1) MY192641A (es)
NZ (1) NZ711460A (es)
PE (1) PE20151601A1 (es)
PH (1) PH12015502047B1 (es)
PL (1) PL2970120T3 (es)
PT (1) PT2970120T (es)
RS (1) RS58136B1 (es)
SG (1) SG11201506280SA (es)
SI (1) SI2970120T1 (es)
SM (1) SMT201800596T1 (es)
TW (1) TWI618698B (es)
UA (1) UA113470C2 (es)
WO (2) WO2014139145A1 (es)
ZA (1) ZA201505999B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072714A1 (en) 2012-11-07 2014-05-15 Karus Therapeutics Ltd Novel histone deacetylase inhibitors and their use in therapy
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
EA035929B1 (ru) 2013-01-15 2020-09-02 Инсайт Холдингс Корпорейшн ТИАЗОЛКАРБОКСАМИДЫ И ПИРИДИНКАРБОКСАМИДЫ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Pim-КИНАЗЫ
US9862685B2 (en) 2013-05-10 2018-01-09 Karus Therapeutics Limited Histone deacetylase inhibitors
SG11201601259YA (en) 2013-08-23 2016-03-30 Incyte Corp Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
WO2018072707A1 (zh) * 2016-10-18 2018-04-26 保诺科技(北京)有限公司 芳香族醚类衍生物、其制备方法及其在医药上的应用
WO2018090973A1 (zh) * 2016-11-17 2018-05-24 广东众生药业股份有限公司 Fgfr4抑制剂及其制备方法和应用
CN108503593B (zh) * 2017-02-28 2021-04-27 暨南大学 2-氨基嘧啶类化合物及其应用
CN108570032B (zh) * 2017-03-09 2021-04-02 华东理工大学 新型罗丹明染料及其在抗致病菌中的应用
CN107382836A (zh) * 2017-08-04 2017-11-24 吴赣药业(苏州)有限公司 一种1‑(4‑氨基苯基)‑1h‑吡啶‑2‑酮的制备方法
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
AU2020367905A1 (en) * 2019-10-14 2022-04-21 Hutchison Medipharma Limited The salts of a compound and the crystalline forms thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0406809A (pt) * 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
WO2005002673A1 (en) * 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
AU2006227628A1 (en) * 2005-03-16 2006-09-28 Targegen, Inc. Pyrimidine compounds and methods of use
US20070161645A1 (en) * 2005-11-02 2007-07-12 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
US8030487B2 (en) * 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
US8148361B2 (en) * 2006-11-10 2012-04-03 Bristol-Myers Squibb Company Kinase inhibitors
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
PE20110062A1 (es) * 2008-06-19 2011-03-09 Astrazeneca Ab N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
WO2010086646A1 (en) 2009-01-28 2010-08-05 Karus Therapeutics Limited Scriptaid isosteres and their use in therapy
CA2866611C (en) 2012-02-28 2020-01-07 Astellas Pharma Inc. Nitrogen-containing aromatic heterocyclic compound
ES2702305T3 (es) 2012-03-08 2019-02-28 Astellas Pharma Inc Nuevo producto de fusión de FGFR3

Also Published As

Publication number Publication date
AR095430A1 (es) 2015-10-14
DK2970120T3 (en) 2018-12-10
CN105143185A (zh) 2015-12-09
RS58136B1 (sr) 2019-02-28
WO2014139145A1 (en) 2014-09-18
LT2970120T (lt) 2019-01-10
CL2015002520A1 (es) 2016-03-28
MY192641A (en) 2022-08-29
PL2970120T3 (pl) 2019-03-29
MX2015012363A (es) 2016-02-03
BR112015020772A2 (pt) 2017-07-18
CA2900748A1 (en) 2014-09-18
EA201591301A1 (ru) 2016-03-31
CA2900748C (en) 2017-10-17
EP2970120A1 (en) 2016-01-20
SI2970120T1 (sl) 2019-02-28
AU2014231437B2 (en) 2016-11-17
US20160052926A1 (en) 2016-02-25
PH12015502047B1 (en) 2019-03-08
SG11201506280SA (en) 2015-09-29
HK1212687A1 (zh) 2016-06-17
EP2970120A4 (en) 2016-08-31
US20160024021A1 (en) 2016-01-28
ZA201505999B (en) 2017-11-29
TWI618698B (zh) 2018-03-21
JP2016510774A (ja) 2016-04-11
NZ711460A (en) 2019-05-31
EP2970120B1 (en) 2018-09-12
US9701680B2 (en) 2017-07-11
IL240790B (en) 2019-10-31
CN105143185B (zh) 2018-02-13
IL240790A0 (en) 2015-10-29
SMT201800596T1 (it) 2019-01-11
UA113470C2 (xx) 2017-01-25
CY1121804T1 (el) 2020-07-31
HRP20181906T1 (hr) 2019-02-22
WO2014139465A1 (en) 2014-09-18
TW201439064A (zh) 2014-10-16
JP6109969B2 (ja) 2017-04-05
KR20150126391A (ko) 2015-11-11
AU2014231437A1 (en) 2015-09-03
EA028654B1 (ru) 2017-12-29
ES2697697T3 (es) 2019-01-25
PH12015502047A1 (en) 2016-01-18
PT2970120T (pt) 2018-11-27
MX363397B (es) 2019-03-21
BR112015020772B1 (pt) 2022-06-07
KR101697982B1 (ko) 2017-01-19

Similar Documents

Publication Publication Date Title
PE20151601A1 (es) Compuestos novedosos de pirimidina y piridina y su uso
CY1118739T1 (el) Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
CY1125613T1 (el) 4-ιμιδαζοπυριδαζιν-1-υλ-βενζαμιδια και 4- ιμιδαζοτριαζιν-1-υλ-βενζαμιδια ως αναστολεις βτκ
PE20161416A1 (es) Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
NI201400151A (es) 7H - PIRROLO [ 2, 3 - d ] PIRIMIDINAS 4 - ( AMINO - SUBSTITUIDAS ) NOVEDOSAS COMO INHIBIDORES DE LRRK2.
CY1118135T1 (el) Παραγωγα 2-(φαινυλο ή πυριδ-3-υλο) αμινοπυριμιδινης ως ρυθμιστες κινασης lrrk2 για τη θεραπευτικη αντιμετωπιση της νοσου του parkinson
CY1118969T1 (el) Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20160869A1 (es) Derivados novedosos de amino pirimidina
CY1116423T1 (el) Ενωσεις δις(φθοροαλκυλο)-1,4-βενζοδιαζεπινονης
CY1117719T1 (el) Παραγωγα αμινοπυριμιδινης ως διαμορφωτες της lrrk2
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
AR078045A1 (es) Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
PE20170268A1 (es) Compuestos de heteroarilo para la inhibicion de cinasa
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20160540A1 (es) Inhibidores de bromodominios
PE20140245A1 (es) Compuesto de furo[3,2-d]pirimidina
EA201400338A1 (ru) Производные аминопиримидина для применения в качестве модуляторов киназной активности
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20151001A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos

Legal Events

Date Code Title Description
FG Grant, registration